Page 27 - Michael Erman News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Novavax said on Thursday it has agreed to pay back international vaccine group Gavi at least $475 million in cash or vaccines by the end of 2028, settling a dispute over canceled orders that had created financial uncertainty for the U.S. maker of COVID-19 shots. Gavi, an alliance that co-finances vaccine purchases with low-income countries, paid Novavax $700 million over 2021 and 2022 for up to 350 million doses of its COVID vaccine. Novavax, which launched its vaccine after several competitors due to manufacturing and regulatory delays, did not deliver any doses before the contract's d...

Moderna fell as much as 7% on Friday after Wall Street analysts raised concerns over faster declines in the efficacy of its experimental respiratory syncytial virus vaccine when compared with rival...

(This Feb. 9 story has been corrected to say efficacy of Pfizer's shot fell from 89% to 79% in the mid-season two, not to 49% from 67% in 17 months, in ...

By Deena Beasley (Reuters) -Gilead Sciences on Tuesday said fourth-quarter revenue dipped 4% on lower sales of HIV drugs and its infused COVID-19 treatment ...

Drugmaker Bristol Myers Squibb on Friday posted better-than-expected results for the fourth quarter as sales of its new anemia drug Reblozyl and its already off patent blood cancer drug Revlimid...